Literature DB >> 10026814

Molecular pharmacology of human vasopressin receptors.

M Thibonnier1, D M Conarty, J A Preston, P L Wilkins, L N Berti-Mattera, R Mattera.   

Abstract

Vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by activation of specific G protein-coupled receptors (GPCRs) currently classified into V1-vascular (V1R), V2-renal (V2R) and V3-pituitary (V3R) AVP receptors and OT receptors (OTR). The cloning of the different members of the AVP/OT family of receptors now allows the extensive molecular pharmacological characterization of a single AVP/OT receptor subtype in stably transfected mammalian cell lines. The human V1-vascular (CHO-V1), V2-renal (CHO-V2), V3-pituitary (CHO-V3) and oxytocin (CHO-OT) receptors stably expressed in CHO cells display distinct binding profiles for 18 peptide and 5 nonpeptide AVP/OT analogs. Several peptide and nonpeptide compounds have a greater affinity for the V1R than AVP itself. V2R peptide agonists and antagonists tend to be non-selective ligands whereas nonpeptide V2R antagonists are potent and subtype-selective. None of the 22 AVP/OT analogs tested has a better affinity for the human V3R than AVP itself. Several peptide antagonists do not select well between V1R and OTR. These results underscore the need for developing specific and potent analogs interacting specifically with a given human AVP/OT receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10026814     DOI: 10.1007/978-1-4615-4871-3_34

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  23 in total

Review 1.  Genetics of vasopressin receptors.

Authors:  Marc Thibonnier
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

2.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Authors:  Cristiana Griffante; Andrew Green; Ornella Curcuruto; Carl P Haslam; Bryony A Dickinson; Roberto Arban
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 3.  Congenital nephrogenic diabetes insipidus: the current state of affairs.

Authors:  Daniel Wesche; Peter M T Deen; Nine V A M Knoers
Journal:  Pediatr Nephrol       Date:  2012-03-17       Impact factor: 3.714

4.  ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement.

Authors:  D Miljic; M Joksimovic; M Doknic; M Ivovic; M Djurovic; S Pekic; M Tancic; I Soldatovic; M Stojanovic; Dj Nale; Dj Macut; S Damjanovic; V Popovic
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

5.  The influence of vasopressin deficiency and acute desmopressin administration on melatonin secretion in patients with central diabetes insipidus.

Authors:  S B Catrina; R Rotarus; I-L Wivall; M Coculescu; K Brismar
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

Review 6.  Management of hyponatraemia in older people: old threats and new opportunities.

Authors:  Roy L Soiza; Hannah S C Talbot
Journal:  Ther Adv Drug Saf       Date:  2011-02

Review 7.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

8.  A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein.

Authors:  Nallini Vijayarangan Adikesavan; Syed Saad Mahmood; Nithianantham Stanley; Zhen Xu; Nan Wu; Marc Thibonnier; Menachem Shoham
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-03-24

Review 9.  The Changing Role of Sodium Management in Cirrhosis.

Authors:  Blanca Lizaola; Alan Bonder; Elliot B Tapper; Angela Mendez-Bocanegra; Andres Cardenas
Journal:  Curr Treat Options Gastroenterol       Date:  2016-06

10.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.